RxDoctor Payments Data

Roberto Torres-Aguiar, MD

Cardiovascular Disease · Winter Park, FLNPI 1326093592

Payments from drug & device makers

$11,674in general payments, 2019–2025

Across 397 payments — averaging $29.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Medtronic$1K
  • Johnson & Johnson$959
  • Boston Scientific$839
  • Abbott$632
  • AstraZeneca$626
  • plus $6K from 41 others

What the payments were for

  • Travel & lodging$1,32111%
  • Food & beverage$9,22379%
  • Education$1,13010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,674 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$317,666
Medicare patients
764
Services billed
3,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$340,477
EntrestoSacubitril/Valsartan251$288,577
FarxigaDapagliflozin Propanediol157$149,200
Repatha SureclickEvolocumab100$100,349
JardianceEmpagliflozin65$72,672
OzempicSemaglutide49$71,506
XareltoRivaroxaban46$58,332
BrilintaTicagrelor77$56,624
MounjaroTirzepatide33$38,437
KerendiaFinerenone11$16,235
Bosentan11$15,361
Prasugrel Hcl36$13,159
NexletolBempedoic Acid21$11,802
Metoprolol Succinate616$7,622
Eplerenone87$7,385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$167$340,477293 claims
NovartisEntresto$419$288,577251 claims
AstraZenecaFarxiga, Brilinta$626$205,824234 claims
Boehringer IngelheimJardiance$353$72,67265 claims
Novo NordiskOzempic$80$71,50649 claims
Johnson & JohnsonXarelto$959$58,33246 claims
BayerKerendia$196$16,23511 claims
Actelion Pharmaceuticals US, Inc.Bosentan$58$15,36111 claims
Esperion Therapeutics, Inc.Nexletol$251$11,80221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →